Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20103706 | 0.86 | THRB (0.39) | THRBCYP3A4SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL12736733 | 0.78 | PKM (0.39) | THRBPKMKDM4EKMT2A | |
| SCHEMBL19271799 | 0.78 | DGAT1 (0.40) | RAB9APKM | |
| SCHEMBL25975362 | 0.77 | RAB9A (0.50) | THRBCYP3A4SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL1679811 | 0.76 | HSD11B1 (0.39) | THRBCYP3A4MAPK1 | |
| SCHEMBL12858249 | 0.75 | RAB9A (0.53) | THRBSMN1; SMN2MAPK1RAB9APKM | |
| SCHEMBL4317039 | 0.75 | THRB (0.34) | THRBPKM | |
| SCHEMBL17132562 | 0.75 | THRB (0.34) | THRB | |
| SCHEMBL19271801 | 0.75 | GLA (0.32) | — | |
| SCHEMBL13139424 | 0.73 | POLB (0.37) | THRBCYP3A4SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| EP-2136803-A1 | TRIAZOLE DERIVATIVES WHICH ARE SMO ANTAGONISTS | Merck & Co., Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008130552-A1 | TRIAZOLE DERIVATIVES WHICH ARE SMO ANTAGONISTS | MERCK & CO., INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK1, IRAK3 | THRB 1233/4885CYP3A4 1768/4885SMN1; SMN2 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.